Effect of soy phytoestrogen on metabolic and hormonal disturbance of women with polycystic ovary syndrome

Journal of Research in Medical Sciences

Volumn 16, Issue 3, 2011, Pages 297-302

  Khani, Behnaz ^a   Mehrabian, Ferdous ^a   Khalesi, Elaheh ^a   Eshraghid, Azadeh ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular Diseases; Genistein; Phytoestrogens; Polycystic Ovary Syndrome

Indexed keywords

CELLULOSE; FOLLITROPIN; GENISTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PLACEBO; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOCRINE DISEASE; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC DISORDER; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOYBEAN; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79955505661     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Mehrabian F, Khani B, Kelishadi R, Ghanbari E. The prevalence of polycystic ovary syndrome in Iranian women based on differentdiagnostic criteria. Polish journal of endocrinology 2011. [In Press].
2. th ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 470-83.
3. Erdman JW Jr. AHA Science Advisory: soy protein and cardiovascular disease, a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 2000; 102(20): 2555-9.
4. De Ugarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83(5): 1454-60.
5. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111(8): 607-13.
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81(1): 19-25.
7. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352(12): 1223-36.
8. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril 2005; 83(5): 1343-6.
9. McCartney CR, Prendergast KA, Chhabra S, Eagleson CA, Yoo R, Change RJ, et al. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab 2006; 91(5): 1714-22.
10. Botros R, Rizk MB. Infertility and assisted reproduction. Cambridge: Cambridge University Press; 2001. p. 246-7.
11. st ed. Oxford: CRC Press; 2005. p. 210-1.
12. Bhathena SJ, Velasquez MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 2002; 76(6): 1191-201.
13. Jayagopal V, Albertazzi P, Kilpatrick ES, Howarth EM, Jennings PE, Hepburn DA, et al. Beneficial effect of Soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 2002; 25(10): 1709-14.
14. Lau DC, Yan H, Dhillon B. Metabolic syndrome: a marker of patients at high cardiovascular risk. Can J Cardiol 2006:22(Suppl B): 85B-90B.
15. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of the metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 2003: 61(1): 29-37
16. Lukaczer D, Liska DJ, Lerman RH, Darland G, Schiltz B, Tripp M, et al. Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women. Nutrition 2006; 22(2): 104-13.
17. Szkudelska K, Nogowski L. Genistein--a dietary compound inducing hormonal and metabolic changes. J Steroid Biochem Mol Biol 2007; 105(1-5): 37-45.
18. Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2007; 85(4): 1148-56.
19. Zhuo XG, Melby MK, Watanabe S. Soy isoflavone intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans. J Nutr 2004; 134(9): 2395-400.
20. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol in humans: a meta-analysis. Eur J Clin Nutr 2003: 57(8): 940-6.
21. Lissin LW, Cooke JP. Phytoestrogens and cardiovascular health. J Am Coll Cardiol 2000;35(6):1403-10.
22. Azadbakht L, Esmaillzadeh A. A randomized cross-over trial on soy intake and serum leptin levels in postmenopausal women with metabolic syndrome. J Res Med Sci 2010; 15(6); 317-23.
23. Wiseman H, O'Reilly JD, Adlercreutz H, Mallet AI, Bowey EA, Rowland IR, et al. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low density lipoprotein to oxidation in humans. Am J Clin Nutr 2000; 72(2): 395-400.
24. Azadbakht L, Esmaillzadeh A. Soy and cardio-metabolic abnormalities: an update. 2008; 13(2): 88-96.
25. Ohno S, Nakajima Y, Inoue K, Nakazawa H, Nakajin S. Genistein administration decreases serum corticosterone and testosterone levels in rats. Life Sci 2003; 74(6): 733-42.
26. Romualdi D, Costantini B, Campagna G, Lanzone A, Guido M. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study. Fertil Steril 2008; 90(5): 1826-33.
27. Kurzer MS. Hormonal effects of soy isoflavones: studies in premenopausal and postmenopausal women. J Nutr 2000; 130(3): 660S-1S.